We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

REFR:NASDAQResearch Frontiers Incorporated Analysis

Data as of 2026-09-05 - not real-time

$0.41

Latest Price

9/10Risk

Risk Level: High

Executive Summary

At $0.4147, Research Frontiers Incorporated shows a bearish moving-average alignment, with shorter averages beneath longer ones. Across the trailing 30 sessions it lost 10.9%. Relative strength is 37.7 — approaching oversold — and the MACD signal is bearish. Price has been bracketed by support at $0.4000 and resistance at $0.5300.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Revenue is contracting at 33.5%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 79.3%, a beta of 1.18 and a maximum drawdown of 83.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Short, medium and long-term reads agree on sell, with conviction of 7/10.

Top Market Events

WOODBURY, NY, Aug. 03, 2026 GLOBE NEWSWIRE -- Research Frontiers Inc.  Nasdaq: REFR  announced today that it will...WOODBURY, N.Y., Aug. 06, 2026 GLOBE NEWSWIRE -- Research Frontiers Inc. Nasdaq: REFR announced its financial results...KLIM AND RESEARCH FRONTIERS ENTER INTO LICENSING AGREEMENT.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 0.94
  • MACD momentum is negative

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 0.94
  • 30-day volatility of 79.3%

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Negative return on equity of -154.0%
  • Revenue contracting at -33.5%
  • Negative free cash flow

Key Metrics & Analysis

Financial Health

Revenue Growth-33.50%
P/E Ratio-6.9
ROE-154.02%
ROA-50.41%
Debt/Equity97.46
P/B Ratio8.1
Op. Cash Flow$-1560698
Free Cash Flow$-597432
Industry P/E33.2

Technical Analysis

TrendBearish
RSI37.7
Support$0.40
Resistance$0.53
MA 20$0.45
MA 50$0.48
MA 200$0.94
MACDBearish
VolumeIncreasing
Fear & Greed Index95.48

Valuation

GradeOvervalued
TypeBlend

Risk Assessment

Beta1.18
Volatility79.26%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.